All In Biotech

Drug Trial Radar · NCT07005154

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Aug 19, 2025

Primary completion

May 31, 2032

Study completion May 31, 2032

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy. ASP5541 is a different form of abiraterone acetate. It is given as an injection into the muscle. In this study, ASP5541 will be given to men with advanced prostate cancer, both with and without prednisone/prednisolone. This study will check the safety of ASP5541 and compare how well ASP5541 works in men with advanced prostate cancer compared to abiraterone acetate. The main aims of the study are: * To check how well ASP5541 with prednisone/prednisolone works compared to AA with prednisone/prednisolone in men with advanced prostate cancer who haven't previously been treated with an ARPI. * To check the safety of ASP5541 given by itself in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check how well ASP5541 given by itself works compared to AA with prednisone/prednisolone in men with advanced prostate cancer that haven't previously been treated with an ARPI. * To check the safety of ASP5541 with prednisone/prednisolone in Japanese men with advanced prostate cancer. Adult men with a certain type of advanced prostate cancer can take part. Their cancer has spread to other parts of the body (metastatic). The different types are: * Metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer that needs testosterone to grow. * Metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer that continues to grow even when testosterone levels are low. In this study there will be 3 treatment groups: * In Group 1, men with mCRPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 and prednisone/prednisolone or be given abiraterone acetate and prednisone/prednisolone. * In Group 2, men with mHSPC who haven't previously been treated with an androgen receptor pathway inhibitor will either be given ASP5541 by itself or be given abiraterone acetate with prednisone/prednisolone. * In Group 3, Japanese men with mCRPC or mHSPC who may or may not have previously been treated with an androgen receptor pathway inhibitor will be given ASP5541 with prednisone/prednisolone. ASP5541 will be given as an injection into a muscle every 12 weeks. Men with mCRPC will take prednisone/prednisolone twice daily and men with mHSPC will take prednisone/prednisolone once daily. Abiraterone acetate will be given as tablets to be taken once daily. All groups will also receive the standard of care treatment, such as androgen deprivation therapy. The men in the study will visit their clinic regularly during and after treatment for health checks, including checking for any medical problems. Some men (Group 2) will check their blood pressure weekly at home. On some visits they will also have scans to check for any changes in their cancer. The number of visits and type of safety checks done at each visit will depend on the health of each person and when they completed their treatment.

Conditions

  • Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Hormone Sensitive Prostate Cancer

Interventions

  • ASP5541Drug

    Intramuscular Injection

  • PrednisoneDrug

    Oral

  • PrednisoloneDrug

    Oral

  • abiraterone acetateDrug

    Oral

  • Adrenocorticotropic hormoneDrug

    Intramuscular or intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of androgen receptor pathway inhibitor (ARPI) -naïve metastatic castration-resistant prostate cancer (mCRPC) participants with Prostate Specific Antigen (PSA) decline ≥ 90% (Cohort 1)Time frame: Up to 37 months
  2. Rate of no mineralocorticoid toxicity (Cohort 2 Group A, Safety run-in)Time frame: Up to 37 months
  3. Proportion of metastatic hormone-sensitive prostate cancer (mHSPC) participants with prostate-specific antigen (PSA) ≤ 0.2 ng/mL (Cohort 2)Time frame: At 8 months
  4. Dose-limiting toxicities (DLTs) (Cohort 3)Time frame: Up to Day 28
  5. Number of participants with Adverse Events (AEs) (Cohort 3)Time frame: Up to 39 months
  6. Number of Participants With Serious Adverse Events (SAEs) (Cohort 3)Time frame: Up to 39 months
  7. Number of participants with laboratory value abnormalities and/or AEs (Cohort 3)Time frame: Up to 37 months
  8. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs (Cohort 3)Time frame: Up to 36 months
  9. Number of participants with vital sign abnormalities and/or AEs (Cohort 3)Time frame: Up to 37 months
  10. Number of participants with physical exam abnormalities and/or AEs (Cohort 3)Time frame: Up to 36 months
  11. Eastern Cooperative Oncology Group (ECOG) Performance Status (Cohort 3)Time frame: Up to 36 months

Locations

54 sites in 12 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama · Recruiting

  • Sharp HealthCare - Sharp Memorial Hospital

    San Diego, California · Recruiting

  • H. Lee Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Associated Urological Specialists

    Chicago Ridge, Illinois · Recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois · Recruiting

  • Ochsner Health - Ochsner Medical Center - New Orleans

    New Orleans, Louisiana · Recruiting

  • New Mexico Oncology Hematology Consultants

    Albuquerque, New Mexico · Recruiting

  • Solaris Health - The Urology Group

    Cincinnati, Ohio · Recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Recruiting

  • Tennessee Oncology Nashville

    Nashville, Tennessee · Recruiting

  • University of Virginia Cancer Center

    Charlottesville, Virginia · Recruiting

  • UW Health Carbone Cancer Center

    Madison, Wisconsin · Recruiting

  • Huai'an First People's Hospital

    Huaian, China · Recruiting

  • Renji Hospital Shanghai Jiaotong Univ School of Medicine

    Shanghai, China · Recruiting

  • Subei People's Hospital

    Yangzhou, Jiangsu, China · Recruiting

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Site FR33003

    Bordeaux, France · Recruiting

  • Site FR33009

    Le Mans, France · Recruiting

  • Site FR33008

    Lille, France · Recruiting

  • Site FR33006

    Paris, France · Recruiting

  • Site FR33004

    Strasbourg, France · Recruiting

  • Site DE49001

    Heinsberg, Germany · Recruiting

  • Site DE49004

    Nürtingen, Baden-Wurttemberg, Germany · Recruiting

  • Site IT39004

    Milan, Italy · Recruiting

  • Site IT39006

    Milan, Italy · Recruiting

  • Site IT39005

    Roma, Italy · Recruiting

  • Site IT39003

    Trento, Italy · Recruiting

  • Harasanshin Hospital

    Fukuoka, Japan · Recruiting

  • Osaka International Cancer Institute

    Osaka, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Shizuoka Cancer Center

    Sunto-gun, Shizuoka, Japan · Recruiting

  • Nippon Medical School Hospital

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Koto, Tokyo, Japan · Recruiting

  • Site PL48003

    Gdansk, Poland · Recruiting

  • Site PL48007

    Gliwice, Poland · Recruiting

  • Site PL48005

    Mysłowice, Poland · Recruiting

  • Site PL48008

    Otwock, Poland · Recruiting

  • PanOncology Trials

    San Juan, Puerto Rico · Recruiting

  • Site KR82006

    Daegu, South Korea · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.